.Attribute Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free and general survival, triggering FDA approval and also a new therapy choice for patients.